N/A N=140 Treatment for Migraines With an Implantable Device
Migraine
Primary: Migraine Frequency at 12 Weeks — -5.5; -3.9 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=155 Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c From Baseline — -1.27; -1.04 percentage change in HbA1c — p=<0.001
N/A N=88 Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage
Hemorrhage
Primary: CBC Hemoglobin Measurement Compared to Non-invasive Radical-7 Measurement — 10.7; 9.2 grams per deciliter
Phase 3 N=501 Evaluation of Vitamin D Requirements During Pregnancy
Vitamin D Deficiency
Primary: 25-Hydroxyvitamin D Concentration — 32.5; 41.0; 45.7 ng/mL
Phase 2 N=18 Anastrozole in Patients With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Plasma Estradiol (E2) Level — -40; -4 % change from baseline
Phase 3 N=174 An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
Hemophilia A
Primary: Treatment Success — 92.4; 92.2; 92.3 % bleeding events successfully treated
Phase 3 N=16,568 Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date — 275; 251; 265; 246 Participants…
Phase 4 N=20 Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying
Obesity
Primary: Gastric Emptying Half-time (T 1/2) of Solids — 187; 86 minutes — p=<.001
Phase 2 N=56 A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Locally Recurrent · Metastatic Breast Cancer ( HER2 Negative)
Primary: Objective Response Rate (ORR) — 28.6 Percentage of participants
Phase 2 N=42 Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
Lung Cancer
Primary: PERCIST Partial Metabolic Response — 6 participants
Phase 3 N=37 A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza
Influenza
Primary: Percentage of Participants Excreting Resistant Virus — 26.3; 35.3 percentage of participants — p=0.825
N/A N=314 T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
Non-small Cell Lung Cancer Stage III · Non-Small-Cell Lung Cancer Metastatic
Primary: Number of Patients With T790M Mutation Detected by Amplification Refractory Mutation System (ARMS) Assay — 97 participants
N/A N=215 Empowering Patients On Choices for Renal Replacement Therapy (Aim 1)
Chronic Kidney Disease
Primary: Factors That Are Most Important to Patients — 98; 93; 97; 100 % of patients
N/A N=453 Comparison of 3 Techniques for Ultrasound-guided Femoral Nerve Catheter Insertion
Total Knee Replacement Surgery
Primary: Time Weighted Average Verbal Response Scale Pain Score — 3.52; 3.24; 3.40 units on a scale — p=< 0.001
Phase 4 N=147 Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE)
Rheumatoid Arthritis
Primary: Change From Baseline in Morning Stiffness Duration at Week 12 as Assessed by Patient Diary — -16.76 minutes